Shares of Novavax Inc. plunged in extended trading on Tuesday after the biotech drugmaker posted more than double the loss analysts had expected and reorganized on concern it might not be in business for a year. .
“While our current cash flow forecast for the prospective one-year going concern period estimates that we have sufficient capital available to finance operations, this forecast is subject to significant uncertainty, including as it relates to revenue. 2023, US Government Funding, and Pending Arbitration,”…